Komzifti (ziftomenib)
New molecular entityPriority review
- Region
- 🇺🇸 US
- Active substance
- ziftomenib
- Company
- Kura
- Status
- Approved
- FDA approval
- Thu 13 Nov 2025
- Designations
- New molecular entity, Priority review
- Application
- NDA220305
- Official record
- www.accessdata.fda.gov
Regulatory milestones
Thu 13 Nov 2025🇺🇸 FDA approval
FDA approves Komzifti (ziftomenib), a new medicine
Kura; NDA220305; New molecular entity, Priority review; capsule · source
Follow Komzifti
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.